Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 and Oxaliplatin with Radiotherapy in Gastric Cancer
NCT01106066Phase 2Terminated
- Sponsor
- Samsung Medical Center
- Start
- Mar 2009
- Primary completion
- Nov 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal adenocarcinoma, sponsored by Samsung Medical Center. Primary endpoint: Maximum Tolerated Dose. Started Mar 2009; status: terminated.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT01106066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01106066.